Grifols, S.A.
HealthcareNASDAQ:GRFS · NASDAQ Global Select
+$0.17 today
Vol 0.45M · Avg 0.72M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$7.4B of revenue converted into $415.6M of net income for the selected period. Gross margin is 37.7% and net margin is 5.6%, showing how much revenue survives after costs and taxes. EPS is $0.61, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.2B +0.2% | $7.2B +9.4% | $6.6B +8.7% | $6.1B +22.9% | $4.9B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $4.6B +5.2% | $4.4B +7.5% | $4.1B +6.7% | $3.9B +29.6% | $3.0B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $2.6B -7.7% | $2.8B +12.5% | $2.5B +12.2% | $2.2B +12.8% | $2.0B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 35.7% -3.0pp | 38.7% +1.1pp | 37.7% +1.2pp | 36.5% -3.3pp | 39.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $358.3M -6.7% | $384.0M -2.8% | $395.3M +9.5% | $361.1M +1.8% | $354.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $1.0B -10.7% | $1.1B -9.6% | $1.3B +14.2% | $1.1B +4.4% | $1.1B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.4B -13.1% | $1.6B -5.8% | $1.7B +18.9% | $1.4B +4.7% | $1.4B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $432.2M -1.3% | $437.9M -1.9% | $446.4M +8.6% | $411.0M +14.2% | $359.8M | $374.2M | $1.2B | $631.8M |
| EBITDA | $1.6B +9.4% | $1.5B +26.9% | $1.2B -2.0% | $1.2B +26.4% | $944.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 22.5% +1.9pp | 20.6% +2.8pp | 17.7% -1.9pp | 19.7% +0.5pp | 19.1% | 5.6% | 46.3% | 42.0% |
| Operating Income | $1.2B -0.4% | $1.2B +52.4% | $782.3M -0.0% | $782.4M +31.5% | $595.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 16.4% -0.1pp | 16.5% +4.7pp | 11.9% -1.0pp | 12.9% +0.8pp | 12.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $32.7M -32.0% | $48.1M -23.0% | $62.4M +84.4% | $33.9M +193.1% | $11.6M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $600.3M -22.4% | $773.2M +49.8% | $516.1M +16.1% | $444.5M +90.1% | $233.8M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$596.5M +20.3% | -$748.0M -30.0% | -$575.3M -29.4% | -$444.4M -81.7% | -$244.6M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $590.7M +33.0% | $444.0M +114.5% | $207.0M -38.8% | $338.0M -3.5% | $350.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 8.2% +2.0pp | 6.2% +3.0pp | 3.1% -2.4pp | 5.6% -1.5pp | 7.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $110.5M -52.2% | $231.2M +433.3% | $43.3M -51.9% | $90.1M +5.9% | $85.1M | $1.3B | -$1.6B | $745.2M |
| Net Income | $386.1M +146.1% | $156.9M +270.8% | $42.3M -77.1% | $185.0M -2.0% | $188.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | 5.3% +3.2pp | 2.2% +1.5pp | 0.6% -2.4pp | 3.1% -0.8pp | 3.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $1 +147.8% | $0 +155.6% | $0 -71.0% | $0 +14.8% | $0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 +147.8% | $0 +155.6% | $0 -71.0% | $0 +14.8% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $680.6M +0.1% | $680.0M +0.0% | $679.8M -0.0% | $679.8M -0.3% | $681.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $680.6M +0.1% | $680.0M +0.0% | $679.8M -0.0% | $679.8M -0.3% | $681.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
DaVita Inc.
NYSE:DVA
$13.45B
Globus Medical, Inc.
NYSE:GMED
$10.85B
Molina Healthcare, Inc.
NYSE:MOH
$10.42B
Masimo Corporation
NASDAQ:MASI
$9.42B
Henry Schein, Inc.
NASDAQ:HSIC
$9.28B
Corcept Therapeutics Incorporated
NASDAQ:CORT
$8.96B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.26B
Bio-Rad Laboratories, Inc.
NYSE:BIO
$7.70B
AptarGroup, Inc.
NYSE:ATR
$7.50B
Avantor, Inc.
NYSE:AVTR
$6.47B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does GRFS generate?
Grifols, S.A. (GRFS) reported $7.23B of revenue in fiscal 2025.
Is GRFS profitable?
Grifols, S.A. (GRFS) reported $386.13M of net income, with a net margin of 5.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.